David Brandariz-Núñez1, Virginia Hernández-Corredoira2, Eva Guarc-Prades3, Bárbara García-Navarro4. 1. Pharmacy Unit, Hospital Quironsalud Barcelona, Barcelona. vrandariz@gmail.com. 2. Pharmacy Unit, Hospital Quironsalud Barcelona, Barcelona. virginia.hernandez@quironsalud.es. 3. Pharmacy Unit, Hospital Quironsalud Barcelona, Barcelona. eva.guar@quironsalud.es. 4. Pharmacy Unit, Hospital Quironsalud Barcelona, Barcelona. barbara.garcia@quironsalud.es.
Abstract
OBJECTIVE: Collect and analyze all the described cases of optic neuropathy associated with linezolid. METHOD: A systematic review of cases was carried out through a search in PubMed-Medline, Embase and ScienceDirect, between September 2002 and April 2018. The demographic, clinical and ophthalmology characteristics of each patient were evaluated. RESULTS: A total of 33 cases from 26 independent articles were analyzed. The mean age was 44.97 ± 21.40 years (range: 6-79) and 16 (50%) of 32 cases were women. The duration of treatment with linezolid until onset of symptoms was greater than 28 days in 29 (90.6%) of 32 documented cases. The mean time of exposure to onset of symptoms was 8.5 ± 8.6 months (range: 0.33-50). A total of 12 of 26 adult patients received linezolid 600 mg/24 h, starting. In 30 (90.9%) patients loss of visual acuity was documented. Linezolid was withdrawn in all cases once the diagnosis was confirmed, with clinical improvement in 31 (93.9%) cases. Conclusions: Optic neuropathy is a reversible complication related to the prolonged use of linezolid and regardless of the dose. We recommend follow- up in patients with long treatments (> 28 days) and ophthalmological exploration in those with visual alterations for the early diagnosis of neuropathy and early withdrawal of linezolid. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.
OBJECTIVE: Collect and analyze all the described cases of optic neuropathy associated with linezolid. METHOD: A systematic review of cases was carried out through a search in PubMed-Medline, Embase and ScienceDirect, between September 2002 and April 2018. The demographic, clinical and ophthalmology characteristics of each patient were evaluated. RESULTS: A total of 33 cases from 26 independent articles were analyzed. The mean age was 44.97 ± 21.40 years (range: 6-79) and 16 (50%) of 32 cases were women. The duration of treatment with linezolid until onset of symptoms was greater than 28 days in 29 (90.6%) of 32 documented cases. The mean time of exposure to onset of symptoms was 8.5 ± 8.6 months (range: 0.33-50). A total of 12 of 26 adult patients received linezolid 600 mg/24 h, starting. In 30 (90.9%) patients loss of visual acuity was documented. Linezolid was withdrawn in all cases once the diagnosis was confirmed, with clinical improvement in 31 (93.9%) cases. Conclusions: Optic neuropathy is a reversible complication related to the prolonged use of linezolid and regardless of the dose. We recommend follow- up in patients with long treatments (> 28 days) and ophthalmological exploration in those with visual alterations for the early diagnosis of neuropathy and early withdrawal of linezolid. Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.